A compound of Formula (I) ##STR00001## and pharmaceutically and/or veterinarily acceptable derivatives thereof, wherein: R.sup.1, R.sup.2, R.sup.3 and R.sup.20 are each independently H, Cl, Br, F, I, CF.sub.3, OCF.sub.3, Me or Et; R.sup.4 is het or C.sub.3-7 cycloalkyl optionally substituted by C.sub.1-4 alkyl, C.sub.1-4 alkoxy, alkoxyalkyl containing 2 to 4 carbon atoms or --S--(C.sub.1-4 alkyl); a is 0 or 1; and het is a non-aromatic 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, optionally fused to a 5- or 6-membered carbocyclic group or a second 4-, 5- or 6-membered heterocycle which contains at least one N, O or S heteroatom, wherein the het group is optionally substituted by at least one substituent independently selected from C.sub.1-8alkyl, C.sub.1-8alkoxy, OH, halo, CF.sub.3, OCF.sub.3, SCF.sub.3, hydroxy-C.sub.1-6alkyl, C.sub.1-4alkoxy-C.sub.1-6alkyl and C.sub.1-4alkyl-S--C.sub.1-4alkyl; provided that at least one of R.sup.1, R.sup.2 and R.sup.3 are other than H. The compounds of the invention exhibit activity as both serotonin and noradrenaline re-uptake inhibitors and therefore have utility in a variety of therapeutic areas, for example urinary incontinence.